Clinical trials: Neoadjuvant Treatment
Head and Neck Squamous Cell Carcinoma
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma
The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by chemoradiation (either cisplatin + IMRT or…
- Trial name
- NCT03389477
- Testing
- Palbociclib, Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Gastric Cancer, RCT
Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma
The purpose of this clinical trial is to evaluate whether perioperative ivonescimab in combination with S-1 and oxaliplatin (SOX) is effective in treating locally advanced gastric or gastroesophageal junction (GEJ)…
- Trial name
- Huaxi (NCT07374250)
- Testing
- Ivonescimab (20mg/kg Q3W), Oxaliplatin, S-1
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Sichuan University
Advanced Gastric Cancer
Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer
Abstract Objective: Ramucirumab is a VEGFR2 antagonist. The aim of this trial is to evaluate the efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin and S-1 in neoadjuvant and conversion therapy for…
- Trial name
- NCT06169410
- Testing
- nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab, nab-paclitaxel, lobaplatin, and S-1
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Yang Jianjun, PhD
Breast Cancer
Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer
This is a prospective, non-randomized study which aims to evaluate the response to a neoadjuvant chemotherapy according to the the antitumor immune response in localized breast cancer. 40 patients will be enrolled in the study.
- Trial name
- BREAST IMMUN (NCT01440413)
- Testing
- Blood and tumor sample
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Leon Berard
Endometrium Cancer
Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma
Indoleamine 2,3 dioxygenase 1 (IDO 1) is the major enzyme catabolising the Tryptophan outside the liver. It has been shown that its plays a important role in generating a immunosuppressive micro-environment in tumors.
- Trial name
- CELEBRIDO (NCT03896113)
- Testing
- Celecoxib 200mg capsule
- Where
- 2 sites in Belgium
- Volunteers
- 48 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
This is a randomized, open-label, controlled, multicenter phase 3 study. All patients are resectable microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer.
- Trial name
- NCT07412613
- Testing
- Cadonilimab (AK104), Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 386 people
- Sponsor
- Akeso
Breast Cancer
Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
To evaluate safety and efficacy of vismodegib with standard neoadjuvant chemotherapy in breast cancer patients based on the CTCAE v4 2010 1.
- Trial name
- SHH-CM (NCT02694224)
- Testing
- vismodegib, Paclitaxel, Epirubicin
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Soft Tissue Sarcoma of the Extremity
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity
This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and…
- Trial name
- SU2C-SARC032 (NCT03092323)
- Testing
- Pembrolizumab
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 126 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Ovarian Cancer
Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging
This study evaluates the therapeutic response by modern FMRI and PET techniques with the perspective to exploit multimodal data (fusion MRI/PET).
- Trial name
- IMOVA (NCT02792959)
- Testing
- Functional Imaging previous the second course, Functional Imaging previous the surgery
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Institut Bergonié
Low Back Pain, Mechanical
Comparison of Two Different Fascial Treatments
The aim of this study is to compare the different effects of two different fascial treatments on pain, flexibility and Asian architecture.
- Trial name
- NCT06715969
- Testing
- Myofascial Release Techniques, Myofascial Induction Techniques, classıcal phsyotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Doğan Burak Endamli
Metastatic Colorectal Cancer
Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer
To evaluate the overall response rate of patients with previously untreated unresectable liver-only metastases from colorectal cancer treated with neoadjuvant capecitabine and oxaliplatin plus bevacizumab.
- Trial name
- NCT01022541
- Testing
- Capecitabine, Oxaliplatin, Bevacizumab
- Where
- United Kingdom
- Volunteers
- 47 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy
This study aims to evaluate vinorelbine plus capecitabine combined with trastuzumab versus trastuzumab alone as the adjuvant Treatment of HER2 positive patients following neoadjuvant chemotherapy
- Trial name
- NCT04302441
- Testing
- Vinorelbine, Capecitabine
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Fudan University
Ameloblastoma
Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
Ameloblastoma is the most common benign odontogenic tumor, characterized by high local invasiveness and a high recurrence rate. Currently, surgical treatment is the standard treatment modality.
- Trial name
- NETCAM-RCT (NCT06819605)
- Testing
- Dabrafenib and trametinib (combination)
- Volunteers
- 46 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
MSS-type Low Rectal Cancer，Neoadjuvant Chemoradiotherapy, QL1706
Neoadjuvant Chemoradiotherapy Combined With QL1706 for MSS-Type Low-Rectal Cancer
he goal of this prospective, exploratory clinical trial is to learn if neoadjuvant chemoradiotherapy combined with QL1706 (a dual PD-1/CTLA-4 antibody) can effectively treat in patients with MSS-type low rectal cancer (tumor…
- Trial name
- NCT07866313
- Testing
- Neoadjuvant short-term radiotherapy and chemotherapy + iparomlimab and tuvonralimab, Neoadjuvant long-term radiotherapy and chemotherapy + iparomlimab and tuvonralimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of…
- Trial name
- NCT01031420
- Testing
- single arm dose dense MVAC
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fox Chase Cancer Center
Rectal Cancer
Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer
The purpose of this study is to see whether three new types of MRI techniques used during magnetic resonance imaging (MRI) of the pelvis to look at rectal cancer can help doctors to tell if the tumor is getting better in response…
- Trial name
- NCT01830582
- Testing
- Advanced MR Imaging
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HPV-Negative Squamous Cell Carcinoma
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer
This clinical trial will assess whether or not blood based biomarker testing can be used to personalize cancer treatment for patients with locally advanced head and neck cancer.
- Trial name
- NCT06005324
- Testing
- Paclitaxel, Carboplatin, Cetuximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Chicago
Locally Advanced Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stability-high (MSI-H) locally advanced rectal cancer (LARC).
- Trial name
- NCT04411524
- Testing
- PD-1 antibody, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Pancreatic Cancer
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation…
- Trial name
- NCT03161379
- Testing
- Cyclophosphamide, Nivolumab, GVAX Pancreas Vaccine
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy
Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy
This study aims to develop and validate a deep learning model to predict pathological complete response (pCR) in patients with esophageal squamous cell carcinoma who have undergone neoadjuvant immunochemotherapy.
- Conditions
- Esophageal Squamous Cell Carcinoma, Neoadjuvant Immunochemotherapy, Pathological Complete Response, Deep Learning
- Trial name
- DL-ESCC (NCT07088354)
- Testing
- The high-throughput extraction of large amounts of quantitative image features from medical images
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.